Momelotinib (MMB)

DRUG3 trials

Sponsors

Sierra Oncology LLC - a GSK company

Conditions

EGFR Mutated EGFR TKI Naive Metastatic NSCLCRelapsed Metastatic KRAS-Mutated Non-Small Cell Lung CancerRelapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

TerminatedNCT02206763

Sierra Oncology LLC - a GSK companyEGFR Mutated EGFR TKI Naive Metastatic NSCLC

Start: 2014-10-16End: 2017-02-16Updated: 2019-02-01

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT02244489

Sierra Oncology LLC - a GSK companyRelapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2014-11-05End: 2017-04-05Updated: 2019-02-01

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

TerminatedNCT02258607

Sierra Oncology LLC - a GSK companyRelapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

Start: 2015-03-11End: 2017-02-27Updated: 2019-02-01

Related Papers

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.

2021-11-1315 citations